anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Coccidiosis is an important parasitic protozoan disease in poultry farming, causing huge economic losses in the global poultry industry every year. MicroRNAs (miRNAs) are a class of RNA macromolecules that play important roles in the immune response to pathogens. However, the expression profiles and functions of miRNAs during Eimeria tenella (E. tenella) infection in chickens remain mostly uncharacterized. In this study, high-throughput sequencing of cecal tissues of control (JC), resistant (JR), and susceptible (JS) chickens led to the identification of 35 differentially expressed miRNAs among the three groups. Functional enrichment analysis showed that the differentially expressed miRNAs were mainly associated with the TGF-beta, NF-kB, and Jak-STAT signaling pathways. Notably, gga-miR-2954 was found to be significantly upregulated after coccidial infection. Functional analysis showed that gga-miR-2954 inhibited the production of the inflammatory cytokines IL-6, IL-1β, TNF-α, and IL-8 in sporozoite-stimulated DF-1 cells. Mechanistically, we found that gga-miR-2954 targeted the RORC gene and that RORC promoted the inflammatory response in sporozoite-stimulated DF-1 cells. In conclusion, our study was the first to identify differentially expressed miRNAs in chicken cecal tissue during E. tenella infection and found that gga-miR-2954 regulates the host immune response to coccidial infection in chickens by targeting the RORC gene.
Many women Veterans are of reproductive age and, of those, a substantial number experience mental health concerns. Women Veterans with mental illness are at greater risk for unplanned pregnancy and adverse pregnancy outcomes due to factors unique to mental illness and mental health treatment. In addition, mental health and mental health-related concerns associated with pregnancy (e.g. impact of pregnancy on mental health, psychiatric medication use during pregnancy) often affect reproductive life decisions and health outcomes. For these reasons, reproductive life planning (RLP), setting personal goals and plans regarding reproductive intentions, that incorporates considerations and addresses concerns specific to mental health conditions is particularly important for women with mental illness. Despite this need, women Veterans with mental illness rarely receive RLP, and current tools do not adequately consider or address the unique reproductive health considerations women with mental illness often experience.

The investigators adapted existing RLP materials to create an interactive, client-centered RLP intervention specifically designed to address mental health considerations that can influence RLP decisions and outcomes in women Veterans with mental illness. Women Veterans work with a facilitator to explore pregnancy intentions and RLP goals; consider important factors that impact those goals (e.g. medical, mental health or psychosocial concerns); and identify steps to address their RLP goals. As such, the RLP-MH intervention may empower women Veterans with mental illness to take an active role in their reproductive health and engage in behaviors that may improve reproductive outcomes. The goal of the proposed study is to pilot-test the RLP-MH intervention in women Veterans with mental illness to evaluate its feasibility and acceptability, and to explore its potential efficacy compared to provision of written materials on RLP (control condition).
The aim of this study was to evaluate the effectiveness of photobiomodulation with a 780 nm laser as an adjunct to surgical treatment in the regeneration of bone fractures. Twenty patients diagnosed with open fractures in the lower limbs were selected and randomly divided into two groups: control and LLLT. LLLT parameter: 780 nm, 0.04 cm2 of light beam diameter, 40 mW of power, 10 s per point, 0.4 J of energy, fluence of 10 J/cm2 and irradiance of 1 W/cm2. The evaluated data were: pain, using McGill scale, use of analgesics and anti-inflammatories, levels of cytokines TNF-α, IFN-γ, IL-1β, IL-10, and IL-17, and bone level regeneration. Data were analyzed using Wilcoxon and Mann-Whitney tests (5%). We can conclude that LLLT was effective as an adjuvant in the bone fracture regeneration process, altered IL-1β levels, reduced the use of analgesics and anti-inflammatories, reducing the pain pattern throughout the sessions.
The invention discloses traditional Chinese medicine micropowder for treating swine streptococcosis and a preparation method thereof. The formula of the traditional Chinese medicine micropowder comprises the following components: 4 to 7 parts of radix bupleuri, 5 to 10 parts of lithospermum, 4 to 8 parts of common andrographis herb, 3 to 6 parts of honeysuckle, 3 to 7 parts of coptis chinensis, 4 to 7 parts of pomegranate peel and 3 to 6 parts of licorice root. The traditional Chinese medicine micropowder is prepared into superfine powder through a superfine grinding technology, so that the components in the medicinal materials are easily absorbed. Thus, the superfine powder can effectively perform antibacterial, antiphlogistic, antipyretic and analgesic functions, and can promote the immunity of a swine so as to rapidly recover the body functions. Therefore, the cure rate of the swine streptococcosis can reach more than 90%; and the problems of the medicine residue and the medicine resistance of pathogenic bacteria in meat products are solved. The traditional Chinese medicine micropowder is an oral preparation which can be directly taken in a mixing and feeding manner, thereby being convenient to use. In addition, the traditional Chinese medicine micropowder is simple in preparation method and low in cost, thereby being suitable for industrialized mass production.
India has one of the highest burdens of childhood undernutrition in the world. The two principal dimensions of childhood undernutrition, namely stunting and underweight can be significantly associated in a particular population, a fact that is rarely explored in the extant literature. In this study, we apply a copula geoadditive modelling framework on nationally representative data of 104,021 children obtained from the National Family Health Survey 5 to assess the spatial distribution and critical drivers of the dual burden of childhood stunting and underweight in India while accounting for this correlation. Prevalence of stunting, underweight and their co-occurrence among under 5 children were 35.37%, 28.63% and 19.45% respectively with significant positive association between the two (Pearsonian Chi square = 19346, P-value = 0). Some of the factors which were significantly associated with stunting and underweight were child gender (Adjusted Odds Ratio (AOR) = 1.13 (1.12) for stunting (underweight)), birthweight (AOR = 1.46 (1.64) for stunting (underweight)), type of delivery (AOR = 1.12 (1.19) for stunting (underweight)), prenatal checkup (AOR = 0.94 (0.96) for stunting (underweight)) and maternal short-stature (AOR = 2.19 (1.85) for stunting (underweight)). There was significant spatial heterogeneity in the dual burden of stunting and underweight with highest prevalence being observed in eastern and western states while northern and southern states having relatively lower prevalence. Overall, the results are indicative of the inadequacy of a "one-size-fits-all" strategy and underscore the necessity of an interventional framework that addresses the nutritional deficiency of the most susceptible regions and population subgroups of the country.
Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics. Sessions will last approximately 90 minutes.
OBJECTIVE: To identify variables that may contribute to the development of proximal junctional failure (PJF) in patients with long lumbo-sacral and thoraco-lumbo-pelvic constructs undergoing anterior column realignment (ACR) with anterior longitudinal ligament release (ALLR).
METHODS: Data of patients with adult spinal deformity who underwent ACR with ALLR at L3-4 were collected retrospectively from medical records and a prospectively maintained spine research database between 2016 and 2022.
RESULTS: Eleven (41%) developed PJF at a mean of 24 ± 21 months from the index surgery. The cohort was then divided into 2 groups for analysis, 13 subjects in the high pelvic incidence (PI) group (defined as PI ≥ 55°) and 14 subjects in the low PI group (defined as PI < 55°). Visual Analog Scale for back pain and Oswestry Disability Index decreased from 9.5 to 2.1 and 61 to 10 in the high PI group, and from 8.9 to 2.4 and 60.9 to 10.3 in the low PI group, respectively. PI (P = 0.004), sacral slope (P = 0.005), and postoperative PI-lumbar lordosis mismatch (P = 0.02) were found to be significant predictors of PJF. The receiver operator curve revealed a cutoff PI value ≤ 53° (95% confidence interval: 52°-64°), below which the risk of PJF becomes significantly higher in patients undergoing ACR with ALLR at L3-4.
CONCLUSIONS: PI may be a predictor of PJF and highly correlates with ACR-ALLR levels. In patients undergoing L3-4 ACR-ALLR, a PI value of ≤53° is associated with a significantly elevated risk of PJF. Preoperative planning of ACR-ALLR level based on normal sagittal alignment in otherwise healthy individuals may mitigate the risk of PJF development in patients with adult spinal deformity treated with ACR-ALLR.
The first phase of our study, previously approved by the UCLA IRB in August 2004, involved a retrospective chart review and collection of preexisting data. We analyzed charts of patients who underwent non-weight-based GH dose adjustments preceded and followed by a serum IGF-I level. Data collected included patient's age, gender, height, weight, linear height velocity, pubertal status, GH dose, IGF-I levels, disease condition (i.e., growth hormone deficiency, idiopathic short stature, small-for-gestational age) and recording of any adverse effects. Based on this data collected, we performed statistical analysis of the relationship between GH dose change and change in IGF-I level achieved, and have found that in prepubertal children, there is a significant relationship between the GH dose change and change in corresponding IGF-I level. We have subsequently constructed a mathematical prediction model that allows us to determine the GH dose change necessary to achieve a desired IGF-I level, and in this second phase of our study, we plan to apply this mathematical prediction model prospectively for guiding GH dose adjustments in prepubertal children being treated with GH therapy.

Children being treated with GH are typically followed in the outpatient Endocrinology clinic every 3-4 months, and our practitioners have routinely been obtaining serum IGF-I levels (via venipuncture in the outpatient laboratory) for monitoring purposes. Validation of our GH dose change/IGF-I change prediction model will require assessment of sequential serum IGF-I level measurements immediately preceding a GH dose change, and again within 1-4 months following the GH dose change. We plan to continue our retrospective and ongoing analysis of patients who have paired values of GH dose adjustments preceded and followed by a serum IGF-I level, in order that we may continue to fine-tune our prediction model for optimizing GH dose adjustments.
An aerosol composition for the diagnosis or treatment of allergies comprises an allergenic material in finely-divided form or in solution in an inert solvent together with an aerosol propellant. Specified propellants are the polyhalogenated lower aliphatic hydrocarbons, such as trichloromonofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane, and trichlorotrifluoroethane, or mixtures thereof. Allergenic materials are defined as finely-divided air-borne particles of household dust and other substances which induce an allergy and which are derived from living organisms and have a cellular structure, including extracts from such substances.  Examples of such materials include spores, pollens, and finely-divided hairs and feathers.  A surface-active agent, e.g. sorbitan trioleate, lecithin, or cetyl pyridinium chloride and/or a finely-divided carrier substance, e.g. powdered lactose or sodium chloride may be included in the aerosol composition.ALSO:A pharmaceutical composition for the diagnosis or treatment of allergies comprises an allergenic material in finely-divided form or in solution in an inert solvent together with an aerosol propellant.  Allergenic materials are defined as finely-divided air-borne particles of household dust and other substances which induce an allergy and which are derived from living organisms and have a cellular structure, including extracts from such substances.  Examples of such materials include spores of fungi, moulds, yeasts or non-flowering plants fungi, moulds, yeasts or non-flowering plants including lichens, pollens of flowering plants and grasses, and finely-divided hairs, feathers, danders and dusts or powders containing spores, pollens, or other material derived from living organisms, as well as the extracts obtainable from the above materials.  The allergenic material may be dispersed in the aerosol propellant with a surface-active agent, e.g. sorbitan trioleate, lecithin, or cetyl pyridinium chloride and/or a finely divided carrier substance, e.g. powdered lactose or sodium chloride.  The pharmaceutical composition is inhaled.
Aqueous anaesthetic solutions, prepared by adding carbon dioxide to an aqueous suspension of a local anaesthetic of the basically substituted acid amide type, e.g. lidocaine, until the anaesthetic base is dissolved, are applied from pressure resistant dispensers in which the propellant may be a mixture of chlorofluorohydrocarbons.ALSO:Aqueous solutions of local anaesthetics of the basically substituted acid amide type are prepared by introducing carbon dioxide, in an amount in excess over that stoichiometrically required for carbonate salt formation, into an aqueous suspension of the anaesthetic, at a temperature not exceeding ambient temperature, until the anaesthetic base has been dissolved. In a modification, an acid addition salt of the anaesthetic base is used together with a water-soluble, acid-neutralizing agent, e.g. sodium bicarbonate, sodium carbonate or sodium hydroxide, in an amount equimolecular to the acid moiety of the addition salt, and carbon dioxide is then introduced to dissolve the liberated base. Anaesthetics specified are lidocaine, mepivacaine, a -(n-propylamino)-propionyl-toluide-(2), (n-butyl-amino)-acetyl-2-methyl-6-chloroanilide and diethylamino-acetyl-2, 6-dimethyl-4-butoxyanilide.  The solutions may be used in vials, ampoules or pressure resistant dispensers and may be incorporated into jellies, ointments and creams.  When used in pressurised form, the propellant may be excess carbon dioxide, nitrogen or a chloro-fluorohydrocarbon.
The invention discloses a medicine for quickly excreting liver ascites. The medicine comprises a traditional Chinese medicine decoction and traditional Chinese medicine pills for synergic treatment, wherein the traditional Chinese medicine decoction is prepared from the following raw materials: rhizoma Atractylodis, bighead atractylodes rhizome, fructus amomi, pericarpium citri reticulatae viride, dried tangerine or orange peel, mangnolia officinalis, fructus aurantii, rhizoma cyperi, elecampane, rush, poria cocos, grifola, rhizoma alismatis, pericarpium arecae and gingers; the traditional Chinese medicine pills are prepared from the following raw materials: semen pharbitidis, morning glory, fresh gingers, dried red dates and brown sugar; the decoction and the pills are prepared by conventional methods. The medicine disclosed by the invention is sufficient in raw materials and low in cost. The decoction and the pills are synergic and combined in action, so that the efficacy of the medicine is overlaid. The medicine is quick to excrete liver ascites, quick in effect, good in effect and short in course of treatment, and the effective rate reaches 98%. The medicine is free from toxic and side effects, simple in preparation method and convenient to take.
Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
A method for accessing, processing, presenting, and/or storing electronic medical record (EMR) information on a touch-sensitive display includes reading EMR information, displaying at least a portion of the EMR information on a touch-sensitive sliding timeline, detecting finger swipe or similar gestures, and scrolling the sliding timeline so that a different portion of the EMR information is displayed chronologically on the touch-sensitive sliding timeline. The resolution of the timeline can be expanded or collapsed in response to pinch gestures. The timeline is divided into a columns, each column including icons representing medical related events. A second timeline having a different time resolution from the first timeline is used for navigating the medical related events. Different levels of detail regarding the medical related events can be viewed in different detail panes. An EMR access device and system are also disclosed, which are configured to access and present EMR information.
Extensive research has shown that lethal photosensitization with low levels of laser light is an effective method of killing numerous types of organisms. This therapy avoids the use of antibiotics along with their potential side effects. The initial application of this therapy to the oral cavity is particularly appropriate since the therapy can be applied topically either in a specific or general fashion, killing is immediate and resistance is unlikely as it is free radical-mediated. In addition, the disease states being treated (gingivitis \& periodontitis) are highly prevalent and associated with significant morbidity. The equipment and costs of this therapy are simple, easily applied and relatively inexpensive compared with current therapies. Based on the scientific data to date this therapy has the potential of significantly improving the oral health of those affected.

This is a pivotal, prospective, randomized, examiner blinded, multicenter study to evaluate the effect of a single treatment of photodynamic disinfection in adults with chronic periodontal disease.
Risk Summary

There are no available human data for the use of JUBLIA during pregnancy to inform any drug associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

In animal reproduction studies, efinaconazole did not cause malformations or any harm to the fetus when administered to pregnant rabbits and rats during the period of organogenesis at subcutaneous doses up to 112 and 154 times, respectively, the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons. Embryolethality was observed only in rats in the presence of maternal toxicity at systemic exposures 559 times the MRHD based on AUC comparisons. Subcutaneous efinaconazole administration to pregnant rats from the beginning of organogenesis through the end of lactation did not cause embryofetal toxicity or developmental effects at systemic exposures 17 times the MRHD based on AUC comparisons (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.

Data

Animal Data

Systemic embryofetal development studies were conducted in rats and rabbits. Subcutaneous doses of 2, 10 and 50 mg/kg/day efinaconazole were administered during the period of organogenesis (gestational days 6-16) to pregnant female rats. In the presence of maternal toxicity, embryofetal toxicity (increased embryofetal deaths, decreased number of live fetuses, and placental effects) was noted at 50 mg/kg/day (559 times the MRHD based on AUC comparisons). No embryofetal toxicity was noted at 10 mg/kg/day (112 times the MRHD based on AUC comparisons). No malformations were observed at 50 mg/kg/day (559 times the MRHD based on AUC comparisons).

Subcutaneous doses of 1, 5, and 10 mg/kg/day efinaconazole were administered during the period of organogenesis (gestational days 6-19) to pregnant female rabbits. In the presence of maternal toxicity, there was no embryofetal toxicity or malformations at 10 mg/kg/day (154 times the MRHD based on AUC comparisons).

In a pre- and postnatal development study in rats, subcutaneous doses of 1, 5 and 25 mg/kg/day efinaconazole were administered from the beginning of organogenesis (gestation day 6) through the end of lactation (lactation day 20). In the presence of maternal toxicity, embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality) was noted at 25 mg/kg/day. No embryofetal toxicity was noted at 5 mg/kg/day (17 times the MRHD based on AUC comparisons). No effects on postnatal development were noted at 25 mg/kg/day (89 times the MRHD based on AUC comparisons).
Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory; however, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment with Bortezomib for Injection. Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 relapsed multiple myeloma trial comparing bortezomib subcutaneous vs intravenous, the incidence of Grade ≥2 peripheral neuropathy was 24% for subcutaneous and 39% for intravenous. Grade ≥3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 15% in the intravenous treatment group [see Adverse Reactions (6.1)]. Starting Bortezomib for Injection subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy.

Patients experiencing new or worsening peripheral neuropathy during Bortezomib for Injection therapy may require a decrease in the dose and/or a less dose-intense schedule [see Dosage and Administration (2.7)]. In the bortezomib vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with ≥Grade 2 peripheral neuropathy following dose adjustment or interruption. Improvement in or resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2 neuropathy or who had ≥Grade 3 peripheral neuropathy in the Phase 2 multiple myeloma studies. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.